Showing results (21-30 of 36) with videos related to
Sort By:
Pageof 4
Inflammatory Bowel Diseases|November 16, 2017
Subcutaneous Golimumab in Pediatric Ulcerative Colitis: Pharmacokinetics and Clinical BenefitJeffrey S Hyams, Daphne Chan, Omoniyi J Adedokun, et al.Journal of the American Academy of Dermatology|April 5, 2023
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Mark Lebwohl, Richard G Langley, et al.Gastroenterology|July 8, 2019
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's DiseaseKatherine Li, Joshua R Friedman, Daphne Chan, et al.Therapeutic Drug Monitoring|June 17, 2006
Chronic prenatal ethanol exposure and increased concentration of fatty acid ethyl esters in meconium of term fetal Guinea pigJames F Brien, Daphne Chan, Courtney R Green, et al.Gastroenterology|June 18, 2018
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's DiseasePaul Rutgeerts, Christopher Gasink, Daphne Chan, et al.Arthritis & Rheumatology (Hoboken, N.J.)|February 11, 2026
Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE StudyAlexis Ogdie, Joseph F Merola, Philip J Mease, et al.BMC Rheumatology|May 21, 2024
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled studyAlexis Ogdie, Joseph F Merola, Philip J Mease, et al.Crohn'S & Colitis 360|February 13, 2023
Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study ResultsJeffrey S Hyams, Christopher D O'Brien, Lakshmi Padgett, et al.Dermatology and Therapy|March 2, 2026
The Impact of Post-inflammatory Pigment Alteration After Psoriasis: Novel Data from the VISIBLE StudyAndrew Alexis, Amy McMichael, Neelam Vashi, et al.Drug Safety|October 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic ArthritisBruce Strober, Laura C Coates, Mark G Lebwohl, et al.Pageof 4